Literature DB >> 28439939

Identification of a polygalacturonase (Cup s 2) as the major CCD-bearing allergen in Cupressus sempervirens pollen.

Y Shahali1,2, J-P Sutra1, C Hilger3, K Swiontek3, I Haddad4, J Vinh4, L Guilloux5, D Charpin6, H Sénéchal1, P Poncet1,7.   

Abstract

As IgE glyco-epitopes, also referred to as cross-reactive carbohydrate determinants (CCDs), can share significant structural homologies between different plants, they are prone to extensive cross-reactivity among allergen pollen extracts. Here, cypress pollen allergens, especially a polygalacturonase (PG), were further characterized using double one-dimensional electrophoresis (D1-DE). The presence of specific IgE directed against CCDs was investigated by bromelain IgE inhibition and concanavalin A binding assays using sera of cypress pollen-sensitized patients. Our results showed that IgE reactivity to CCDs in Cupressus sempervirens pollen extracts is mainly related to bromelain-type epitopes of a newly identified cypress PG. This glycoprotein has been further characterized through an immunoproteomic approach and officially indexed as Cup s 2 by the WHO/IUIS allergen nomenclature. Cup s 2 could thus be associated with the increased prevalence of IgE reactivity to cypress pollen extracts because of CCD interference.
© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  zzm321990Cupressus sempervirenszzm321990; bromelain; cross-reactive carbohydrate determinant; cypress pollen allergens; polygalacturonase

Mesh:

Substances:

Year:  2017        PMID: 28439939     DOI: 10.1111/all.13191

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  1 in total

1.  Pollen/Fruit Syndrome: Clinical Relevance of the Cypress Pollen Allergenic Gibberellin-Regulated Protein.

Authors:  Hélène Sénéchal; Sanaz Keykhosravi; Rémy Couderc; Marie Ange Selva; Youcef Shahali; Tomoyasu Aizawa; Jean Marc Busnel; Rihane Arif; Inna Mercier; Nhan Pham-Thi; Denis André Charpin; Pascal Poncet
Journal:  Allergy Asthma Immunol Res       Date:  2019-01       Impact factor: 5.764

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.